Traws Pharma, Inc. (NASDAQ:TRAW) Receives Consensus Recommendation of “Reduce” from Brokerages

Posted by Brian Himes on Aug 29th, 2026

Shares of Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) have been given an average rating of “Reduce” by the five ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $1.00.

TRAW has been the subject of several research analyst reports. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Traws Pharma in a research note on Tuesday, August 18th. Citigroup cut Traws Pharma to a “neutral” rating in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, LADENBURG THALM/SH SH cut shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th.

Check Out Our Latest Research Report on Traws Pharma

Institutional Trading of Traws Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP lifted its holdings in shares of Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after acquiring an additional 5,955 shares during the last quarter. State Street Corp bought a new position in Traws Pharma in the fourth quarter valued at $29,000. XTX Topco Ltd raised its position in Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after purchasing an additional 31,502 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in Traws Pharma during the fourth quarter valued at about $56,000. Finally, Geode Capital Management LLC lifted its stake in Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after purchasing an additional 18,213 shares during the last quarter. Hedge funds and other institutional investors own 7.95% of the company’s stock.

Traws Pharma Price Performance

NASDAQ TRAW opened at $0.59 on Friday. The company’s 50 day simple moving average is $0.63 and its two-hundred day simple moving average is $1.26. Traws Pharma has a 1 year low of $0.43 and a 1 year high of $3.27. The stock has a market capitalization of $9.07 million, a PE ratio of -0.34 and a beta of 1.57.

Traws Pharma (NASDAQ:TRAW – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.18. On average, research analysts anticipate that Traws Pharma will post -1.2 EPS for the current year.

About Traws Pharma

(Get Free Report)

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.